123 related articles for article (PubMed ID: 30727894)
1. Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma.
Zhang X; Gao F; Zhong S
Curr Cancer Drug Targets; 2019; 19(9):698-706. PubMed ID: 30727894
[TBL] [Abstract][Full Text] [Related]
2. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
Giubellino A; Sourbier C; Lee MJ; Scroggins B; Bullova P; Landau M; Ying W; Neckers L; Trepel JB; Pacak K
PLoS One; 2013; 8(2):e56083. PubMed ID: 23457505
[TBL] [Abstract][Full Text] [Related]
3. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
4. [Research on multiple myeloma cell apoptosis by inhibition of mTORC2 and chaperon pathways].
Fu Y; Zhang Y; Zhang F; Liu J; Gui R
Zhonghua Xue Ye Xue Za Zhi; 2015 Sep; 36(9):780-4. PubMed ID: 26462781
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
[TBL] [Abstract][Full Text] [Related]
6. Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation.
Xu Y; Zhang C; Chen D; Zhao J; Shen Z; Wu Y; Zhu Y
Tumour Biol; 2013 Dec; 34(6):4065-71. PubMed ID: 23873112
[TBL] [Abstract][Full Text] [Related]
7. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Zhang X; Zhong S
Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
[TBL] [Abstract][Full Text] [Related]
8. Effects of geldanamycin on neurite outgrowth-related proteins and kinases in nerve growth factor-differentiated pheochromocytoma 12 cells.
Migita K; Matsumoto T; Terada K; Ono K; Hara S
J Pharmacol Sci; 2019 Jul; 140(3):255-262. PubMed ID: 31402210
[TBL] [Abstract][Full Text] [Related]
9. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
10. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Werfel TA; Wang S; Jackson MA; Kavanaugh TE; Joly MM; Lee LH; Hicks DJ; Sanchez V; Ericsson PG; Kilchrist KV; Dimobi SC; Sarett SM; Brantley-Sieders DM; Cook RS; Duvall CL
Cancer Res; 2018 Apr; 78(7):1845-1858. PubMed ID: 29358172
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the mTORC2 and chaperone pathways to treat leukemia.
Zhang F; Lazorchak AS; Liu D; Chen F; Su B
Blood; 2012 Jun; 119(25):6080-8. PubMed ID: 22566604
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma apoptosis via the AKT/GSK-3β/β-catenin signaling.
Liang GH; Liu N; He MT; Yang J; Liang ZJ; Gao XJ; Rahhal AH; He QY; Zhang HT; Zha ZG
J Cell Biochem; 2018 Jan; 119(1):948-959. PubMed ID: 28681940
[TBL] [Abstract][Full Text] [Related]
13. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice.
Giubellino A; Bullova P; Nölting S; Turkova H; Powers JF; Liu Q; Guichard S; Tischler AS; Grossman AB; Pacak K
Endocrinology; 2013 Feb; 154(2):646-55. PubMed ID: 23307788
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
19. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma.
Holmes B; Benavides-Serrato A; Freeman RS; Landon KA; Bashir T; Nishimura RN; Gera J
Oncogene; 2018 Feb; 37(6):732-743. PubMed ID: 29059166
[TBL] [Abstract][Full Text] [Related]
20. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Holmes JL; Sharp SY; Hobbs S; Workman P
Cancer Res; 2008 Feb; 68(4):1188-97. PubMed ID: 18281495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
